trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary precision cancer monitoring® (pcm) technology in tumor genomics. trovagene has broad intellectual property and proprietary technology to measure circulating tumor dna (ctdna) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. trovagene offers its pcm technology at its clia/cap – accredited laboratory and plans to continue to vertically integrate its pcm technology with precision cancer therapeutics. trovagene's lead therapeutic asset is pcm-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (plk1) inhibitor for the treatment of acute myeloid leukemia (aml). among the four members of the plk family, plk1 is recognized to be the fundamental component for cell division to take place correctly. most importantly, plk1 is only expressed in dividing cells, wh
Company profile
Ticker
CRDF
Exchange
Website
CEO
Mark Erlander
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
TrovaGene Inc., Trovagene, Inc., USED KAR PARTS INC, XENOMICS INC
SEC CIK
Corporate docs
IRS number
43721895
CRDF stock data
Latest filings (excl ownership)
8-K
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
8 Apr 24
S-8
Registration of securities for employees
27 Mar 24
8-K
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
29 Feb 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Pancreatic Cancer and Small Cell Lung Cancer Program Updates
26 Sep 23
8-K
Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 15.23 mm | 15.23 mm | 15.23 mm | 15.23 mm | 15.23 mm | 15.23 mm |
Cash burn (monthly) | 1.38 mm | 290.33 k | 3.61 mm | 3.71 mm | 2.65 mm | 2.76 mm |
Cash used (since last report) | 9.45 mm | 1.99 mm | 24.72 mm | 25.40 mm | 18.18 mm | 18.93 mm |
Cash remaining | 5.78 mm | 13.24 mm | -9.49 mm | -10.17 mm | -2.94 mm | -3.69 mm |
Runway (months of cash) | 4.2 | 45.6 | -2.6 | -2.7 | -1.1 | -1.3 |
Institutional ownership, Q3 2023
27.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 58 |
Opened positions | 7 |
Closed positions | 5 |
Increased positions | 8 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 6.75 bn |
Total shares | 12.26 mm |
Total puts | 56.00 k |
Total calls | 197.00 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
Acorn Bioventures | 3.04 mm | $5.75 mm |
PFE Pfizer | 2.41 mm | $14.98 mm |
Vanguard | 1.94 mm | $2.70 bn |
Venrock Healthcare Capital Partners III | 1.71 mm | $29.66 mm |
Laurion Capital Management | 722.10 k | $1.00 bn |
BLK Blackrock | 717.59 k | $997.45 mm |
Geode Capital Management | 392.31 k | $545.46 mm |
Renaissance Technologies | 154.00 k | $214.00 k |
STT State Street | 139.95 k | $194.52 mm |
Blair William & Co | 130.50 k | $181.40 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Mar 24 | Fairooz Kabbinavar | Stock Options Common Stock | Grant | Acquire A | No | No | 3.51 | 205,008 | 719.58 k | 630,008 |
7 Mar 24 | Tod Smeal | Stock Options Common Stock | Grant | Acquire A | No | No | 3.51 | 205,008 | 719.58 k | 647,184 |
7 Mar 24 | Erlander Mark | Stock Options Common Stock | Grant | Acquire A | No | No | 3.51 | 510,000 | 1.79 mm | 2,170,310 |
7 Mar 24 | Levine James E. | Stock Options Common Stock | Grant | Acquire A | No | No | 3.51 | 205,008 | 719.58 k | 962,496 |
19 Dec 23 | Pace Gary W | Common Stock | Buy | Acquire P | No | No | 1.37 | 30,000 | 41.10 k | 697,761 |
News
Cardiff Oncology Presents Novel Preclinical Data At AACR Annual Meeting 2024; Supports First-Line RAS-Mutated mCRC Clinical Study
8 Apr 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
13 Mar 24
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Raises Price Target to $14
6 Mar 24
Crude Oil Down Over 1%; Quoin Pharmaceuticals Shares Spike Higher
4 Mar 24
Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
4 Mar 24
Press releases
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
8 Apr 24
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?
26 Mar 24
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
15 Mar 24
Thinking about buying stock in SoundHound AI, Kinross Gold, Nu Holdings, Cardiff Oncology, or Turtle Beach?
14 Mar 24
Thinking about buying stock in ShiftPixy, Minim, Cardiff Oncology, Laird Superfood, or Tenon Medical?
13 Mar 24